严重喘的生物疗法:以表型驱动和有针对性的方法
Maria D'Amato1, Daniela Pastore2, Chiara Lupia2
1Respiratory Department, Monaldi Hospital AO Dei Colli, Federico II University, 80131 Naples, Italy.
Journal of clinical medicine
|July 12, 2025
概括
生物标志物,如血中乙氨基和FeNO,有助于选择严重喘的生物疗法. 本综述提供了一个框架,用于个性化治疗决策在不受控制的喘病例.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的喘管理对于那些无法通过标准疗法控制的患者来说仍然具有挑战性.
- 生物药物提供基于炎症内型 (T2-高,T2-低) 的向治疗.
- 选择最佳的生物因重叠的表型和有限的生物标志物而复杂.
研究的目的:
- 审查生物标志物的临床实用性,以指导严重喘的生物治疗.
- 检查影响治疗选择的临床因素和并发症.
- 为选择生物制剂提供一个实际的决策框架.
主要方法:
- 在PubMed.com进行了广泛的文献搜索.
- 关键生物标志物的分析:血液中的乙氨基,FeNO,质素,IgE.
- 临床评估,指导方针和现实生活经验的整合.
主要成果:
- 生物标志物 (乙氨基,FeNO,IgE,质素) 对于患者的分层至关重要.
- 临床特征和并发症影响生物选择.
- 一个决策平台和表与特定的生物制剂 (奥马利祖马布,梅波利祖马布等) 匹配表型. ) 的情况.
结论:
- 整合生物标记分析和临床评估为生物选择提供了一个逻辑框架.
- 这种方法支持个性化药物用于不受控制的严重喘.
- 对于新的生物标志物和长期结果评估,需要进一步的研究.
相关概念视频
Asthma: Pathogenesis and Management
606
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
606
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
471
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
471
Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Antiasthma Drugs: Leukotriene Modifiers
486
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
486
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


